Health Canada has approved Zepbound (tirzepatide) as the first medication in Canada for the treatment of obstructive sleep apnea in obese adults. Eli Lilly photo
Health Canada has granted approval to Zepbound, making it the first treatment in Canada specifically approved for adults with obesity who have moderate-to-severe obstructive sleep apnea.
The one-a-week medication from Eli Lilly Canada has received approval for use in conjunction with a calorie-restricted diet and increased physical activity for adults with a body mass index of 30 or greater.
